申请人:Glaxo Group Limited
公开号:US04650810A1
公开(公告)日:1987-03-17
Compounds are disclosed of general formula (I): ##STR1## wherein R.sub.1, R.sub.3, R.sub.4, R.sub.6 and R.sub.7, which may be the same or different, each represents a hydrogen atom or an alkyl group; R.sub.2 represents a hydrogen atom or an alkyl, aryl, aralkyl, cycloalkyl or alkenyl group; or R.sub.1 and R.sub.2, together with the nitrogen atom to which they are attached, form a saturated monocyclic 5 to 7-membered ring which may optionally contain a further hetero function; R.sub.5 represents a hydrogen atom or an alkyl or alkenyl group; or R.sub.4 and R.sub.5 together form an aralkylidene group; Alk represents an alkylene chain containing two or three carbon atoms which may be unsubstituted or substituted by not more than two C.sub.1-3 alkyl groups; and X represents an oxygen or sulphur atom; and physiologically acceptable salts, solvates and bioprecursors thereof. The compounds are described as potentially useful for the treatment of migraine and may be formulated as pharmaceutical compositions in conventional manner using one or more pharmaceutically acceptable carriers or excipients. Various processes for the preparation of the compounds are disclosed including, for example, a process involving reacting an indole having an appropriate nitrile group at the 5-position, with a suitable oxygen- or sulphur-containing compound in order to introduce the required amide or thioamide group at the 5-position on the indole nucleus.
本发明公开了一般式(I)的化合物:##STR1## 其中,R.sub.1、R.sub.3、R.sub.4、R.sub.6和R.sub.7,可以相同也可以不同,分别代表氢原子或烷基基团;R.sub.2代表氢原子或烷基、芳基、芳基烷基、环烷基或烯基基团;或者R.sub.1和R.sub.2与它们所连接的氮原子一起形成饱和的单环5到7成员环,该环可以选择性地含有进一步的杂原子;R.sub.5代表氢原子或烷基或烯基基团;或者R.sub.4和R.sub.5一起形成芳基烷基亚胺基团;Alk代表含有两个或三个碳原子的烷基链,可以是未取代或取代的,取代基为不超过两个的C.sub.1-3烷基基团;X代表氧原子或硫原子;以及其生理上可接受的盐、溶剂化合物和生物前体。所述化合物被描述为治疗偏头痛的潜在有用药物,并可以用一种或多种药学上可接受的载体或赋形剂在常规方式下制备成药物组成物。公开了各种制备该化合物的方法,包括例如,通过将具有适当的5位腈基的吲哚与适当的含氧或硫化合物反应以在吲哚核上引入所需的酰胺或硫酰胺基团的方法。